ScreenerHero

BCDABioCardia, Inc.

NAS · US · Healthcare · Biotechnology · biocardia.com
1.010USD+1.92%Mkt Cap: 15.29M $P/E: —

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is Car…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap15.29M $
Enterprise Value10.82M $
Revenue (TTM)—
Gross Profit-4.19M $
Net Income (TTM)-8.23M $
Revenue/Share—
Last Price1.010 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.67
PEG—
EV/EBITDA-1.47
EV/Revenue—
P/S—
P/B5.37
EPS (TTM)-0.57
EPS (Forward)-0.58
52W Range
0.750017% of range2.290
52W High2.290 USD
52W Low0.7500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-919.33%
ROA-241.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.44M $
CapEx (TTM)7.00K $
FCF Margin—
FCF Yield-37.02%
Net Debt-3.82M $
Net Debt/EBITDA0.52
Balance Sheet
Debt/Equity0.59
Current Ratio2.09
Quick Ratio2.02
Book Value/Sh0.1800 USD
Cash/Share0.2720 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 6, 2019
Splits
Last Split1:15
Split DateMay 30, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.50 USD
Upside (mean)+1434.7%
Target Range6.000 USD – 25.00 USD
$6.000+1434.7% to mean$25.00
# Analysts2
Ownership
Shares Out.15.14M
Float11.32M
Insiders23.19%
Institutions9.50%
Short Interest
Short Ratio3.0d
Short % Float8.50%
Short % Out.7.44%
Shares Short1.11M
Short (prev mo.)371.80K
Technical
SMA 500.9426 (+7.2%)
SMA 2001.148 (-12.0%)
Beta0.49
S&P 52W Chg18.16%
Avg Vol (30d)284.53K
Avg Vol (10d)201.48K
Technical Indicators
RSI (14)58.3
MACD0.0143
MACD Signal-0.0016
MACD Hist.+0.0159
BB Upper1.052 USD
BB Middle0.8978 USD
BB Lower0.7434 USD
BB Width34.40%
ATR (14)0.0785 USD
Vol Ratio (20d)0.33x